We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immune-Checkpoint Blockade Therapy in Lymphoma.
- Authors
Kuzume, Ayumi; Chi, SungGi; Yamauchi, Nobuhiko; Minami, Yosuke
- Abstract
Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion. Immune-checkpoint blockade can inhibit this signal and may serve as an effective therapeutic strategy in patients with solid tumors. Several trials have been conducted on immune-checkpoint inhibitor therapy in patients with malignant lymphoma and their efficacy has been reported. For example, in Hodgkin lymphoma, immune-checkpoint blockade has resulted in response rates of 65% to 75%. However, in non-Hodgkin lymphoma, the response rate to immune-checkpoint blockade was lower. In this review, we evaluate the biology of immune-checkpoint inhibition and the current data on its efficacy in malignant lymphoma, and identify the cases in which the treatment was more effective.
- Subjects
PROGRAMMED cell death 1 receptors; LYMPHOMAS; HODGKIN'S disease; PROGRAMMED death-ligand 1; CELL physiology; CYTOTOXIC T cells
- Publication
International Journal of Molecular Sciences, 2020, Vol 21, Issue 15, p5456
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms21155456